<DOC>
	<DOCNO>NCT01644825</DOCNO>
	<brief_summary>The purpose study evaluate safety activity add pazopanib weekly chemotherapy paclitaxel patient ovarian cancer resistant refractory treatment platinum base therapy .</brief_summary>
	<brief_title>Weekly Paclitaxel With Without Pazopanib Platinum Resistant Refractory Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Cytologic / histologic diagnosis stage ICIV ovarian cancer Disease progress first line chemotherapy disease relapse within 6 month last platinum treatment Disease evaluable RECIST Ca 125 GCIG criterion No residual peripheral neurotoxicity previous chemotherapy treatment PS 01 Aged least 18 great 75 year . Life expectancy least 3 month Able swallow retain oral medication Written inform consent prior performance study specific procedure assessment Ability willingness comply treatment follow assessment procedure · • Previous concomitant malignant neoplasia ( include basocellular spinocellular skin carcinoma insitu carcinoma uterine cervix , provide adequately treat ) Previous treatment weekly paclitaxel More 2 previous chemotherapy treatment Serious heart disease , include heart failure , atrioventricular block degree , serious arrhythmia history one follow cardiovascular condition within past 6 month : cardiac angioplasty stenting , myocardial infarction , unstable angina , symptomatic peripheral vascular disease , coronary artery bypass graft surgery , class II , III IV congestive heart failure define New York Heart Association ( NYHA ) Hemoglobin &lt; 9 g/dL , neutrophils &lt; 1500/mm3 , platelet &lt; 100000/mm3 Impairment renal function ( patient 2 function kidney ) : creatinine 1.5 time upper normal limit UNL ; calculate creatinine clearance &lt; 50 mL/min ; urine protein creatinine ratio &gt; = 1 : , 24hour urine protein must assess subject must 24hour urine protein value &lt; 1gr eligible Impairment liver function ( SGOT SGPT &gt; = 2.5 UNL , alkaline phosphatase &gt; 2.5 ULN , total bilirubin &gt; 1.5 time UNL ) Prothrombin time ( PT ) international normalize ratio ( INR ) activate partial thromboplastin time ( PTT ) &gt; 1.2 time UNL Pregnancy , breast feeding , inadequate contraception Unable discontinue prohibit medication ( see protocol section 6.7 ) Clinically significant gastrointestinal abnormality might interfere oral dosing , include limited malabsorption syndrome , major resection stomach small bowel could affect drug absorption , active peptic ulcer disease , inflammatory bowel disease , ulcerative colitis , gastrointestinal condition increase risk perforation , history abdominal fistula , gastrointestinal perforation , intraabdominal abscess within 28 day prior begin study treatment , sign symptoms GI obstruction Any unstable serious concurrent condition Prolongation correct QT interval ( QTc ) &gt; 480 ms History cerebrovascular accident , pulmonary embolism untreated deep venous thrombosis ( DVT ) within past 6 month Macroscopic hematuria Major surgery trauma within 30 day Hypertension uncontrolled adequate therapy ( systolic blood pressure ( BP ) &gt; = 140mmHg , diastolic BP &gt; = 90mmHg ) Any ongoing toxicity prior anticancer therapy &gt; Grade 1 and/or progress severity Present suspect haemorrhagic syndrome Patients ' inability access centre due area residence</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>platinum resistant</keyword>
	<keyword>platinum refractory</keyword>
</DOC>